Atrial fibrillation: challenges and opportunities.
Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in clinical practice. There are many pharmacological and nonpharmacological options available for AF patients. There is, however, a great deal of dissatisfaction with the available treatments of this arrhythmia. Furthermore, AF management remains associated with many challenges that make the treatment of AF a vexing problem. The present overview discusses these challenges and explores the opportunities associated with them.
Hersi
Ahmad
A
Libin Cardiovascular Institute of Alberta, University of Calgary, and Calgary Health Region, Alberta.
Mitchell
L Brent
LB
Wyse
D George
DG
D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D020521:Stroke / Q000209:etiology / Q000517:prevention & control
D000889:Anti-Arrhythmia Agents; D005343:Fibrinolytic Agents